Analysis and Commentary STEVEN GROSSMAN 7/22/22 Analysis and Commentary STEVEN GROSSMAN 7/22/22 Untangling FDA’s FY 23 Funding: Appropriations and User Fees Hit Peak Uncertainty Read More Analysis and Commentary STEVEN GROSSMAN 7/15/22 Analysis and Commentary STEVEN GROSSMAN 7/15/22 What Dr. Califf Told Us About His Plans for FDA Read More Analysis and Commentary STEVEN GROSSMAN 7/8/22 Analysis and Commentary STEVEN GROSSMAN 7/8/22 Some Likely Questions at the Alliance Webinar with the Commissioner; Feedback on Alliance Senate Visits Read More Analysis and Commentary Lisa Ellington 6/24/22 Analysis and Commentary Lisa Ellington 6/24/22 Resisting the Impulse to Cut FDA Funding During Times of Controversy Read More Analysis and Commentary Lisa Ellington 6/17/22 Analysis and Commentary Lisa Ellington 6/17/22 Messaging for the Alliance’s Upcoming Senate Hill Meetings Read More Analysis and Commentary Lisa Ellington 6/10/22 Analysis and Commentary Lisa Ellington 6/10/22 Appropriations Mark-ups; the Deeming Resolution; The Possible Return of Hurry Up and Wait Read More Analysis and Commentary Lisa Ellington 6/3/22 Analysis and Commentary Lisa Ellington 6/3/22 Q&A about User Fees, Budget Information, and Reconciliation Read More Analysis and Commentary Lisa Ellington 5/27/22 Analysis and Commentary Lisa Ellington 5/27/22 Excerpts from the Alliance’s Testimony to the House Appropriations Committee’s Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies. Read More Analysis and Commentary Lisa Ellington 5/20/22 Analysis and Commentary Lisa Ellington 5/20/22 What CBER Director Dr. Marks Said to the Alliance Read More Analysis and Commentary Lisa Ellington 5/13/22 Analysis and Commentary Lisa Ellington 5/13/22 What CVM Director Dr. Shuren Said to the Alliance Read More Analysis and Commentary Lisa Ellington 5/6/22 Analysis and Commentary Lisa Ellington 5/6/22 Alliance Members Encouraged to Submit Testimony to House Ag/FDA Subcommittee in Support of the Alliance’s FY 23 “Ask” Read More Analysis and Commentary Lisa Ellington 4/29/22 Analysis and Commentary Lisa Ellington 4/29/22 What Dr. Califf Said to the Senate; What CVM Director Dr. Solomon Said to the Alliance Read More Analysis and Commentary STEVEN GROSSMAN 4/22/22 Analysis and Commentary STEVEN GROSSMAN 4/22/22 Q&A: the President’s Budget Request and our Hill visits to advocate for more FDA funding. Read More Analysis and Commentary STEVEN GROSSMAN 4/15/22 Analysis and Commentary STEVEN GROSSMAN 4/15/22 Summaries of the Alliance webinars with Associate Commissioner for Regulatory Affairs Judy McMeekin and with CFSAN Director Dr. Susan Mayne Read More Analysis and Commentary STEVEN GROSSMAN 4/8/22 Analysis and Commentary STEVEN GROSSMAN 4/8/22 Summary of the Alliance webinar with CDER Director Dr. Patrizia Cavazzoni Read More Analysis and Commentary STEVEN GROSSMAN 4/1/22 Analysis and Commentary STEVEN GROSSMAN 4/1/22 Administration seeks FY23 FDA Increase of $336 Million; New Resources Support Broad Range of FDA Programs. Read More Analysis and Commentary STEVEN GROSSMAN 3/25/22 Analysis and Commentary STEVEN GROSSMAN 3/25/22 Forthcoming FY 23 President’s budget release and what to look for Part 2. Read More Analysis and Commentary STEVEN GROSSMAN 3/18/22 Analysis and Commentary STEVEN GROSSMAN 3/18/22 Forthcoming FY 23 President’s Budget Release and how to interpret the OMB “headline numbers” Part 1 Read More Analysis and Commentary STEVEN GROSSMAN 3/11/22 Analysis and Commentary STEVEN GROSSMAN 3/11/22 Detail on the FDA’s FY 22 funding and implications for the FY 23 cycle. Read More Analysis and Commentary STEVEN GROSSMAN 3/4/22 Analysis and Commentary STEVEN GROSSMAN 3/4/22 Q&A: consequences of delay in FY 22/23 appropriations; Timing for user fee reauthorization. Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 7/22/22 Analysis and Commentary STEVEN GROSSMAN 7/22/22 Untangling FDA’s FY 23 Funding: Appropriations and User Fees Hit Peak Uncertainty Read More
Analysis and Commentary STEVEN GROSSMAN 7/15/22 Analysis and Commentary STEVEN GROSSMAN 7/15/22 What Dr. Califf Told Us About His Plans for FDA Read More
Analysis and Commentary STEVEN GROSSMAN 7/8/22 Analysis and Commentary STEVEN GROSSMAN 7/8/22 Some Likely Questions at the Alliance Webinar with the Commissioner; Feedback on Alliance Senate Visits Read More
Analysis and Commentary Lisa Ellington 6/24/22 Analysis and Commentary Lisa Ellington 6/24/22 Resisting the Impulse to Cut FDA Funding During Times of Controversy Read More
Analysis and Commentary Lisa Ellington 6/17/22 Analysis and Commentary Lisa Ellington 6/17/22 Messaging for the Alliance’s Upcoming Senate Hill Meetings Read More
Analysis and Commentary Lisa Ellington 6/10/22 Analysis and Commentary Lisa Ellington 6/10/22 Appropriations Mark-ups; the Deeming Resolution; The Possible Return of Hurry Up and Wait Read More
Analysis and Commentary Lisa Ellington 6/3/22 Analysis and Commentary Lisa Ellington 6/3/22 Q&A about User Fees, Budget Information, and Reconciliation Read More
Analysis and Commentary Lisa Ellington 5/27/22 Analysis and Commentary Lisa Ellington 5/27/22 Excerpts from the Alliance’s Testimony to the House Appropriations Committee’s Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies. Read More
Analysis and Commentary Lisa Ellington 5/20/22 Analysis and Commentary Lisa Ellington 5/20/22 What CBER Director Dr. Marks Said to the Alliance Read More
Analysis and Commentary Lisa Ellington 5/13/22 Analysis and Commentary Lisa Ellington 5/13/22 What CVM Director Dr. Shuren Said to the Alliance Read More
Analysis and Commentary Lisa Ellington 5/6/22 Analysis and Commentary Lisa Ellington 5/6/22 Alliance Members Encouraged to Submit Testimony to House Ag/FDA Subcommittee in Support of the Alliance’s FY 23 “Ask” Read More
Analysis and Commentary Lisa Ellington 4/29/22 Analysis and Commentary Lisa Ellington 4/29/22 What Dr. Califf Said to the Senate; What CVM Director Dr. Solomon Said to the Alliance Read More
Analysis and Commentary STEVEN GROSSMAN 4/22/22 Analysis and Commentary STEVEN GROSSMAN 4/22/22 Q&A: the President’s Budget Request and our Hill visits to advocate for more FDA funding. Read More
Analysis and Commentary STEVEN GROSSMAN 4/15/22 Analysis and Commentary STEVEN GROSSMAN 4/15/22 Summaries of the Alliance webinars with Associate Commissioner for Regulatory Affairs Judy McMeekin and with CFSAN Director Dr. Susan Mayne Read More
Analysis and Commentary STEVEN GROSSMAN 4/8/22 Analysis and Commentary STEVEN GROSSMAN 4/8/22 Summary of the Alliance webinar with CDER Director Dr. Patrizia Cavazzoni Read More
Analysis and Commentary STEVEN GROSSMAN 4/1/22 Analysis and Commentary STEVEN GROSSMAN 4/1/22 Administration seeks FY23 FDA Increase of $336 Million; New Resources Support Broad Range of FDA Programs. Read More
Analysis and Commentary STEVEN GROSSMAN 3/25/22 Analysis and Commentary STEVEN GROSSMAN 3/25/22 Forthcoming FY 23 President’s budget release and what to look for Part 2. Read More
Analysis and Commentary STEVEN GROSSMAN 3/18/22 Analysis and Commentary STEVEN GROSSMAN 3/18/22 Forthcoming FY 23 President’s Budget Release and how to interpret the OMB “headline numbers” Part 1 Read More
Analysis and Commentary STEVEN GROSSMAN 3/11/22 Analysis and Commentary STEVEN GROSSMAN 3/11/22 Detail on the FDA’s FY 22 funding and implications for the FY 23 cycle. Read More
Analysis and Commentary STEVEN GROSSMAN 3/4/22 Analysis and Commentary STEVEN GROSSMAN 3/4/22 Q&A: consequences of delay in FY 22/23 appropriations; Timing for user fee reauthorization. Read More
